X

Johnson & Johnson (JNJ) TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release

Newsdesk: